"As the conversation around AI grows darker, we risk becoming so consumed by what might go wrong that we stop paying attention to what is beginning to go right," write Alex Karnal and Brian Kreiter.

AN2 Therapeutics looks attractive with a risk-adjusted base-case valuation of approximately $12 per share. Read why I rate ANTX stock a Buy now.

An Analysis, Part 1 With September nearly over, my attention for the next two weeks flips to National Hunt racing, writes Dave Renham. This is the first of a two-parter where I will be looking at a va ...